Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Protein identification of recombinant SLFN11 and SLFN14

ABSTRACT: The Schlafen (SLFN) family of nucleic acid binding proteins play an important role in gene regulation. In response to environmental stress, many SLFN members are activated for RNA cleavage and translational regulation. To characterize the RNA cleavage activity of this protein family, we produced recombinant human SLFN11 and SLFN14 protein. We utilized mass spectrometry for protein identification to confirm the identity of our recombinant SLFN protein samples.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Antrix Jain

LAB HEAD: Monica C. Pillon

PROVIDER: PXD064237 | Pride | 2025-07-08

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	54296_1_MSPCL_1200_hs_SLFN11_one4th.msf	Msf
	54296_1_MSPCL_1200_hs_SLFN11_one4th.pdResult	Other
	54296_1_MSPCL_1200_hs_SLFN11_one4th.raw	Raw
	54296_1_MSPCL_1200_hs_SLFN11_one4th_TargetPeptideSpectrumMatch.txt	Txt
	54297_1_MSPCL_1200_hs_SLFN14_0ne4th.msf	Msf

Items per page:

1 - 5 of 8

Publications

CryoEM structure of the SLFN14 endoribonuclease reveals insight into RNA binding and cleavage.

Van Riper Justin J Martinez-Claros Arleth O AO Wang Lie L Schneiderman Hannah E HE Maheshwari Sweta S Pillon Monica C MC

Nature communications 20250701 1

The SLFN14 endoribonuclease is a post-transcriptional regulator that targets the ribosome and its associated RNA substrates for codon-bias translational repression. SLFN14 nuclease activity is linked to antiviral defense and platelet function. Despite its prominent role in gene regulation, the molecular signals regulating SLFN14 substrate recognition and catalytic activation remain unclear. SLFN14 dysregulation is linked to human diseases, including ribosomopathies and inherited thrombocytopenia ...[more]

PMID: 40592880

Similar Datasets

SLFN11 is widely expressed in pediatric sarcoma and induces variable sensitization to 1 replicative stress caused by DNA damaging agents

Project description:Schlafen family member 11 (SLFN11) increases sensitivity to replicative stress and has been proposed as a biomarker to predict sensitivity to DNA damaging agents (DDA). However, the role of SLFN11 in pediatric cancer has not been well explored. In this study, we found that protein expression strongly correlated with response to the PARP inhibitor talazoparib and the topoisomerase I inhibitor irinotecan in sarcoma cell lines, with SLFN11 knockout resulting in significant loss of sensitivity in vitro and in vivo. However, in contrast to its activity in adult tumors, high SLFN11 expression did not correlate with favorable outcome in a retrospective study of children with sarcoma. Our work suggests that the potential of SLFN11 to act as a biomarker may be limited to certain tumor backgrounds or contexts, and that impaired apoptotic response may be one targetable mechanism of resistance to DDA-induced replicative stress

2022-04-08 | GSE181094 | GEO

Critical regulatory roles of SLFN11 on NF-kB signaling and its effects on glioblastoma growth and survival

Project description:Glioblastoma (GBM) is an aggressive and incurable brain tumor in nearly all instances, whose disease progression is driven in part by the glioma stem cell (GSC) subpopulation. Here, we explored the effects of Schlafen family member 11 (SLFN11) in the molecular, cellular and tumor biology of GBM.

2023-03-10 | PXD033913 | Pride

Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress [ATAC-seq_CPTO]

Project description:Schlafen 11 (SLFN11) has recently arisen as a novel cellular restriction factor against replication stress. Here we show that SLFN11 increases chromatin accessibility genome-wide, dominantly at promoters in response to replication stress induced by the CHK1 inhibitor prexasertib and the topoisomerase I inhibitor, camptothecin. Concomitantly SLFN11 selectively activates cellular stress response pathways by inducing the transcription of the Immediate Early Genes (IEGs) including JUN, FOS, EGR1, NFKB2 and ATF3. Both chromatin opening and IEG activation require the putative helicase activity of SLFN11 whereas extrinsic IEG activation by serum induction is SLFN11-independent. SLFN11-dependent IEG activation is also observed across 55 non-isogenic NCI-60 cell lines by comparing transcriptome data before and after camptothecin treatment. We conclude that SLFN11 acts as a global regulator of chromatin structure and an intrinsic IEG activator with the potential to engage the native immune activation in response to replicative stress.

2020-01-17 | GSE140933 | GEO

Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress [ATAC-seq_CHPTCHK1i]

2020-01-17 | GSE140932 | GEO

Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress [RNA-seq_CPT]

2020-01-17 | GSE140937 | GEO

Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress [RNA-seq_CHK1i]

2020-01-17 | GSE140936 | GEO

Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress [ChIP-seq_H3K27ac_CPTO]

2020-01-17 | GSE140935 | GEO

Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress [ATAC-seq_K562]

2020-01-17 | GSE140934 | GEO

Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress [microarray]

2020-01-17 | GSE140175 | GEO

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer

Project description:Large independent analyses on cancer cell lines followed by functional studies have identified Schlafen 11 (SLFN11), a putative helicase, as the strongest predictor of sensitivity to DNA-damaging agents (DDA), including platinum. However, its role as a prognostic biomarker is undefined, partially due to the lack of validated methods to score SLFN11 in human tissues. Here, we implemented a pipeline to quantify SLFN11 in human cancer samples. By analyzing a cohort of high-grade serous ovarian carcinoma (HGSOC) specimens prior platinum-based chemotherapy treatment, we show, for the first time, that SLFN11 density in both the neoplastic and microenvironmental components was independently associated with favorable outcome. We observed SLFN11 expression in both infiltrating innate and adaptive immune cells, and analyses in a second, independent, cohort revealed that SLFN11 is associated with immune activation in HGSOC. We found that platinum treatments activated immune-related pathways in ovarian cancer cells in a SLFN11-dependent manner, representative of tumor-immune transactivation. Moreover, SLFN11 expression was induced in activated, isolated, immune cell subpopulations, hinting that SLFN11 in the immune compartment may be an indicator of immune transactivation. In summary, we propose SLFN11 is a dual biomarker capturing simultaneously interconnected immunological and cancer-cell-intrinsic functional dispositions associated with sensitivity to DDA treatment.

2021-07-13 | GSE179896 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data